These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6356452)

  • 1. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood.
    Kluft C; Jie AF; Allen RA
    Thromb Haemost; 1983 Aug; 50(2):518-23. PubMed ID: 6356452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.
    Rijken DC; Juhan-Vague I; de Cock F; Collen D
    J Lab Clin Med; 1983 Feb; 101(2):274-84. PubMed ID: 6681623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrinsic plasminogen activator response to exercise after a single dose of propranolol.
    el-Sayed MS
    Med Sci Sports Exerc; 1992 Mar; 24(3):327-32. PubMed ID: 1549027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
    Huisman LG; van Griensven JM; Kluft C
    Thromb Haemost; 1995 Mar; 73(3):466-71. PubMed ID: 7667830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C; Collen D
    Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
    Korninger C; Collen D
    Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on C1 inactivator resistant fibrinolytic activity].
    Deguchi A; Kawamura K; Deguchi K; Tamaki S; Tanigawa M; Iwasaki E; Wada H; Murashima S; Nishikawa M; Shirakawa S
    Rinsho Byori; 1991 May; 39(5):517-22. PubMed ID: 2072575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic studies in 13 unrelated families with factor XII deficiency.
    Rodeghiero F; Castaman G; Ruggeri M; Cazzavillan M; Ferracin G; Dini E
    Haematologica; 1991; 76(1):28-32. PubMed ID: 2055558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia].
    Astedt B; Fagner U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):475-9. PubMed ID: 6083913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.
    Korninger C; Stassen JM; Collen D
    Thromb Haemost; 1981 Oct; 46(3):658-61. PubMed ID: 7198302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
    Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
    J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway.
    Kluft C; Wijngaards G; Jie AF
    J Lab Clin Med; 1984 Mar; 103(3):408-19. PubMed ID: 6199446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.
    Rijken DC; Juhan-Vague I; Collen D
    J Lab Clin Med; 1983 Feb; 101(2):285-94. PubMed ID: 6681624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
    Brommer EJ; Verheijen JH; Chang GT; Rijken DC
    Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-like plasminogen activator increased in plasma after alcohol drinking.
    Sumi H; Hamada H; Tsushima H; Mihara H
    Alcohol Alcohol; 1988; 23(1):33-43. PubMed ID: 3128990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
    Pannell R; Kung W; Gurewich V
    J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of plasminogen activators from human plasma and a comparison with activators from human uterine tissue and urine.
    Kok P
    Thromb Haemost; 1979 Jun; 41(4):734-44. PubMed ID: 483246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.